Core Insights - TScan Therapeutics, Inc. announced updated results from the ALLOHA Phase 1 trial of TSC-101, demonstrating favorable relapse-free survival and overall survival in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation [1][2][3] Group 1: Trial Results - The treatment arm showed a relapse-free survival (RFS) hazard ratio of 0.50 (p=0.23) and overall survival (OS) hazard ratio of 0.61 (p=0.52) compared to the control arm [1][3] - 100% of TSC-101-treated patients who reached two-year follow-up remained relapse-free, while only 25% in the control arm did [1][3] - Among the treatment arm, 21% relapsed compared to 33% in the control arm, indicating a lower relapse rate [3] Group 2: Safety and Tolerability - TSC-101 was well-tolerated with no dose-limiting toxicities observed, and adverse events were similar across both treatment and control arms [1][9] - The new commercial-ready manufacturing process reduced the manufacturing time from 17 days to 12 days, enhancing efficiency [9] Group 3: Future Plans - The company plans to initiate a pivotal study in the second quarter of 2026, focusing on enrolling remaining patients to support a fixed-dosing regimen [2][4] - TScan aims to expand its hematologic malignancies program in 2026 with additional product candidates to double the addressable patient population [2]

Core Insights - TScan Therapeutics, Inc. will host a virtual key opinion leader event to discuss updated data from the ALLOHA Phase 1 trial and future market opportunities for its heme program [1][2] - The event will include a review of two-year relapse data from the ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies [2] - The company has implemented an improved commercial-ready manufacturing process for the ALLOHA Phase 1 trial, which will be utilized in the upcoming pivotal trial set to begin in Q2 2026 [2] Company Overview - TScan Therapeutics is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer treatment [4] - The lead therapy candidate is aimed at preventing relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation [4] - The company is also developing multiple TCR-T therapy candidates for solid tumors and exploring novel targets in T cell-mediated autoimmune disorders through its TargetScan platform [4]